Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 09, 2023 07:00 ET | Source: Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals Highlights Strategic Priorities for 2023

Enrollment Progresses in SUNRISE-3 Global Phase 3 Registrational Trial of Bemnifosbuvir in High-Risk Non-Hospitalized Patients with COVID-19 with Interim Analysis Expected 2H23 Proof-of-Concept...
January 04, 2023 07:00 ET | Source: Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference

BOSTON, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that Jean-Pierre Sommadossi, PhD, Chief...
November 29, 2022 07:00 ET | Source: Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals Announces First Patient Dosed in SUNRISE-3 Phase 3 Registrational Trial of Bemnifosbuvir, an Investigational Oral Antiviral for the Treatment of COVID-19

Global Study to Evaluate Bemnifosbuvir as Monotherapy and in Combination in Non-Hospitalized Patients at High Risk of Disease Progression, Regardless of Vaccination Status Phase 3 Evaluation of...
November 22, 2022 07:00 ET | Source: Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals to Present at the 5th Annual Evercore ISI HealthCONx Conference

BOSTON, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that Jean-Pierre Sommadossi, PhD, Chief...
November 08, 2022 16:05 ET | Source: Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals to Present at the Jefferies London Healthcare Conference

BOSTON, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that Jean-Pierre Sommadossi, PhD, Chief...
November 07, 2022 16:05 ET | Source: Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update

Enrollment of SUNRISE-3 Global Phase 3 Registrational Trial of Bemnifosbuvir in High-Risk Non-Hospitalized Patients with COVID-19 Expected Before Year-End 2022 Completion of Patient Enrollment...
November 03, 2022 07:00 ET | Source: Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals Presents Favorable AT-752 Phase 1 Data for Treatment of Dengue Fever at American Society of Tropical Medicine & Hygiene 2022 Annual Meeting

Safety and pharmacokinetic data in healthy volunteers support ongoing clinical development AT-752 is a novel, orally administered, direct-acting antiviral in Phase 2 development with a Fast Track...
October 31, 2022 07:00 ET | Source: Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals to Host Third Quarter 2022 Financial Results Conference Call on November 7, 2022

BOSTON, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that it will host a live conference call and...
September 26, 2022 07:00 ET | Source: Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals Announces U.S. FDA Fast Track Designation Granted to AT-752 for Treatment of Dengue

Dengue is the most prevalent mosquito-borne viral disease; endemic to 100 countries worldwide, with more than half the world’s populations at-risk AT-752 is a novel, orally administered,...
September 13, 2022 07:00 ET | Source: Atea Pharmaceuticals, Inc.

Atea to Advance Global Phase 3 Registrational Study of Bemnifosbuvir in High-Risk Non-Hospitalized Patients with COVID-19

Novel Phase 3 Trial Design to Evaluate Bemnifosbuvir as Monotherapy and Combination Antiviral Therapy for COVID-19 Trial to Focus on High-Risk Patients at Greatest Risk for Disease Progression ...